Brief: Novo Nordisk Aims To Deliver 2026-30 Revenue CAGR In Line With Industry Peers
BRIEF-Novo Nordisk Aims To Deliver 2026-30 Revenue CAGR In Line With Industry Peers Sept 21 (Reuters) - Novo Nordisk A/S NOVOb.CO:
HIGHLIGHTS TO BE PRESENTED AT NOVO’S CAPITAL MARKETS DAY 2026
AMBITION FOR 2030: SCALE CAPACITY TO BE ABLE TO SERVE 10X MORE PEOPLE WITH OBESITY ON ORAL GLP-1
CMD UPADE TO COVER: AIM DELIVER 2026-30 REVENUE CAGR IN LINE WITH INDUSTRY PEERS
CMD UPDATE TO COVER: AIM TO MAINTAIN BROADLY STABLE OPERATING MARGIN
Source text: ID:nGNE1pSR0L
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals